Biogen vs Gilead Sciences
Gilead Sciences reported revenue of $29.4 billion in fiscal 2025, 3.0 times Biogen's $9.9 billion in fiscal 2025. Biogen's revenue grew 2.2% in its latest year, and Gilead Sciences' grew 2.4%. Free cash flow was $2.1 billion at Biogen and $9.5 billion at Gilead Sciences.
Side by side
| Biogen | Gilead Sciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $9.9B | $29.4B |
| Revenue growth | 2.2% | 2.4% |
| Revenue growth a year, last 5 years | −6.0% | 3.6% |
| Gross margin | 75.7% | 78.8% |
| Operating margin | — | 34.0% |
| Net margin | 13.1% | 28.9% |
| Free cash flow | $2.1B | $9.5B |
| Free cash flow margin | 20.7% | 32.1% |
| Return on capital | 7.3% | 22.9% |
| Net debt to EBITDA | 0.9x | 1.4x |
| Dividends and buybacks | $0M | $5.9B |
| Change in diluted share count | 0.8% | 0.0% |
| Last close | $252.26 | $158.69 |
| P/E at the last close | 27.1× | — |
| Insider trades, last 12 months | bought $585, sold $905,414 | sold $85.8 million |
| Piotroski F-score | 5 of 9 | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BiogenGilead Sciences
Operating margin
Percent of revenue
BiogenGilead Sciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BiogenGilead Sciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Biogen and Gilead Sciences pages.